Skip to main content

Table 4 2006 Versus 2015 direct ophthalmic medical costs and patient value gain versus ranibizumab therapy for first two years

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Cost

2006

2015

Physician

$6167 (11.7%)

$2611 (5.6%)

Ranibizumab

$44,812 (85.2%)

$42,665 (91.9%)

Diagnostic tests

$1230 (2.3%)

$1174 (2.5%)

Post-operative antibiotics

$414 (0.8%)

$0 (0.0%)

Total

$52,652 (100%)

$46,450 (100%)

Adjusted with medical CPI to 2015 US $

$70,161

$46,450

Decrease in real dollars from 2006 to 2015

NA

−33.8%

Patient value (quality-of-life) gain

2006

2015

First-eye model

6.4%

9.8%

Second-eye model

15.8%

22.8%

Combined-eye model

10.4%

16.3%

  1. Parentheses indicate percent of total direct ophthalmic medical costs. NA not applicable. Note that patient value gain = quality-of-life gain